A Phase 1 Dose Escalation Study of ARQ 197 Given Twice Daily Continuously in Adult Patients With Advanced Solid Tumors.

Trial Profile

A Phase 1 Dose Escalation Study of ARQ 197 Given Twice Daily Continuously in Adult Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2012

At a glance

  • Drugs Tivantinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Jul 2012 Actual patient number changed from 46 to 51 as reported by ClinicalTrials.gov.
    • 17 Feb 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 01 Jun 2009 Status changed from recruiting to completed. Final results in were presented at ASCO.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top